(Scale All Share (Ref.), Retail, TPG GR)



Buy EUR 16.00	(EUR 17.00)	Value Indicators: DCF: Peer group:	EUR 16.02 22.97	Warburg Risk Score: Balance Sheet Score: Market Liquidity Score:	2.4 3.8 1.0	Description: The Platform Group provides service B2B/B2C e-commerce platform	
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2025e
		Market cap:	205	Freefloat	30.00 %	Beta:	1.5
Price	EUR 10.05	No. of shares (m):	20	Dr. Dominik Benner	70.00 %	Price / Book:	1.4 x
Upside	59.2 %	EV:	314	Paladin Asset Management	9.90 %	Equity Ratio:	44 %
o policio	00.2 /0	Freefloat MC:	62			Net Fin. Debt / EBITDA:	1.9 x
		Ø Trad. Vol. (30d):	490.38 th			Net Debt / EBITDA:	1.9 x

New business segment is formed, Optics & Hearing

The Platform Group has announced the acquisition of a majority share in two optician groups Beste Aussichten GmbH and Karrasch & Nolte GmbH. In total, both companies operate approx. 30 locations with 200 employees. The purchase price was not disclosed but should be in the double-digit millions and will be financed with a cash component and share compensation. Closing is expected in July.

TPG aims to extend its optician and hearing-aid business further and will report its operations in the new business segment, Optics & Hearing. On a pro-forma basis, the group expects to generate EUR 30m in sales and an adj. EBITDA of 8-10m this year. In a first step, both targets will be merged with the online platform My Glasses, which will be opened up for external partners by the end of the year and provide local opticians and hearing-aid acousticians with access to e-commerce. In a second step, TPG aims to expand its business further with additional acquisitions and is already in negotiations with 15 potential targets from Germany and neighbouring EU countries. Driven by new partners and additional acquisitions, the group intends to grow its Optics & Hearing segment to EUR 55-60m in sales at an EBITDA margin of at least 25% in 2026.

We have included the two targets in our model assuming that they will be consolidated starting in August, with a top-line contribution of EUR 12.5m and an EBITDA contribution of EUR 3.1m. For 2026, we assumed the consolidation on a full-year basis and an EBITDA margin of 25%, but did not consider additional acquisitions. Since the purchase price was not disclosed, we assumed a price of 5x EBITDA and a stake of 50.1%. We have modelled the purchase price of EUR 25m as if it was fully paid in cash. We believe that our assumptions are conservative considering that TPG has paid less than 5x EBITDA in most of the recent take-overs and that the share component of the transaction should lead to a lower net debt/EBITDA compared to our estimates.

Despite the increase in our forecast, we reduce the target price slightly from EUR 17 to EUR 16. The main reason for the lower target price is an increase in our applied WACC to reflect the recent change in the legal form to a KGaA and the high interest on the bond which is currently at 9%. We are not expecting that new shares will be offered to shareholders, but as an acquisition currency.

In conclusion, TPG continues its successful buy-and-build strategy with these two acquisitions. After the negative reaction to the change in the legal form, which offset the positive share-price response to the strong first quarter, we consider the current valuation with a PE 26e of 7.2x highly attractive. After adjusting our estimates and our target price we confirm our Buy recommendation for TPG.

Changes in E	stimates:					
FY End: 31.12. in EUR m	2025e (old)	+/-	2026e (old)	+/-	2027e (old)	+/-
Sales	691	1.8 %	752	4.2 %	809	4.1 %
EBITDA adj.	50	4.5 %	61	7.9 %	65	10.6 %
EBITDA	54	4.2 %	61	7.9 %	65	10.6 %
Net income	22	3.7 %	27	10.3 %	30	11.5 %

Comment on Changes:

- 2025 estimates include the recent acquisitions assuming consolidation as of August
- For 2026 we assumed consolidation on a full-year basis
- Our 2026 estimates for the Optics & Hearing segment are below the company's forecast, since we have not considered additional acquisitions.




Rel. Performance vs Scale	All Share
1 month:	-13.7 %
6 months:	26.8 %
Year to date:	16.7 %
Trailing 12 months:	3.7 %

Company events:	
26.06.25	AGM
22.08.25	Q2
14.11.25	Q3

FY End: 31.12.	CAGR							
in EUR m	(24-27e)	2021	2022	2023	2024	2025e	2026e	2027e
Sales	17.1 %	241	387	441	525	703	784	842
Change Sales yoy		153.9 %	61.0 %	13.8 %	19.0 %	34.1 %	11.4 %	7.5 %
Gross profit margin		34.3 %	29.8 %	26.1 %	32.2 %	28.3 %	28.2 %	28.3 %
EBITDA	8.8 %	7	37	47	56	56	65	72
Margin		3.1 %	9.5 %	10.8 %	10.6 %	8.0 %	8.3 %	8.5 %
EBITDA adj.	29.1 %	7	12	23	33	52	65	72
Margin		3.1 %	3.1 %	5.1 %	6.3 %	7.5 %	8.3 %	8.5 %
EBIT	7.8 %	2	26	39	46	43	51	57
Margin		0.9 %	6.6 %	8.9 %	8.7 %	6.1 %	6.5 %	6.8 %
Net income	2.0 %	2	19	26	31	23	30	33
EPS	0.4 %	0.30	1.12	1.50	1.60	1.13	1.45	1.62
DPS	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
FCFPS		-2.89	0.41	3.06	2.56	1.10	0.96	1.54
FCF / Market cap		-10.3 %	5.4 %	55.8 %	33.4 %	10.9 %	9.5 %	15.3 %
EV / Sales		0.9 x	0.6 x	0.4 x	0.5 x	0.4 x	0.4 x	0.3 x
EV / EBITDA		28.2 x	6.2 x	3.4 x	4.5 x	5.6 x	4.5 x	3.7 x
EV / EBIT		92.3 x	8.9 x	4.1 x	5.5 x	7.3 x	5.7 x	4.6 x
P/E		93.7 x	6.7 x	3.6 x	4.8 x	8.9 x	6.9 x	6.2 x
FCF Potential Yield		3.5 %	14.9 %	25.4 %	20.8 %	15.6 %	18.8 %	22.5 %
Net Debt		34	99	69	101	109	90	58
ROCE (NOPAT)		2.9 %	17.0 %	23.4 %	23.2 %	13.4 %	14.3 %	15.1 %
Guidance: 2	2025: GMV E	UR 1.3bn, sa	les EUR 680	-700m, adj. E	BITDA EUR	47-50m		






Company Background

- The Platform Group offers an e-commerce platform solution, connecting smaller stationary retailers from a wide range of industries to large number of online stores, owned and operated by TPG and third-party websites.
- The Consumer Goods segment comprises B2C platform activities with conventional parcel sizes and is focused on customer as well as sales optimization. The Fashionette business is also included in this BU.
- Business activities in Freight Goods specializes in products with more complex logistic requirements such as furniture retailers, bicycles,
 e-scooters and car-subscription platforms.
- Industrial Goods comprises platforms for new & used machinery, bottling, dental care, barber-shop supplies and car parts. The segment is focused in B2B specific marketing, management, logistics and after-sales service.
- The Service & Retail Goods segment comprises e-commerce services for pharmacies, real-estate businesses and online learning platforms. The 10 legacy stores owned by TPG also contribute to this business unit.

Competitive Quality

- Scalable e-commerce platform for stationary and smaller businesses based on a proprietary software solution, which is not trivial to replicate.
- Large and growing partner and customer base from a diversified spectrum of industries.
- Striving for a cycle of growth by expanding product offering which triggers positive feedback and attracts more consumers, which in turn increases the platform's value.
- Solid margins even compared with larger peers despite tough competition for customers from major online retailers in each industry.
- Pure platform approach limits requirements for capex and working capital





DCF model														
	Detaile	d forecas	t period				7	ransition	al period					Term. Value
Figures in EUR m	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	2036e	2037e	
Sales	703	784	842	901	964	1,027	1,089	1,148	1,206	1,266	1,329	1,376	1,404	
Sales change	34.1 %	11.4 %	7.5 %	7.0 %	7.0 %	6.5 %	6.0 %	5.5 %	5.0 %	5.0 %	5.0 %	3.5 %	2.0 %	2.0 %
EBIT	43	51	57	63	66	67	67	69	70	70	73	76	77	
EBIT-margin	6.1 %	6.5 %	6.8 %	7.0 %	6.8 %	6.5 %	6.2 %	6.0 %	5.8 %	5.5 %	5.5 %	5.5 %	5.5 %	
Tax rate (EBT)	22.0 %	24.0 %	26.0 %	28.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	
NOPAT	33	39	42	45	46	47	47	48	49	49	51	53	54	
Depreciation	13	14	14	14	15	16	17	18	19	20	21	22	22	
in % of Sales	1.9 %	1.8 %	1.7 %	1.6 %	1.6 %	1.6 %	1.6 %	1.6 %	1.6 %	1.6 %	1.6 %	1.6 %	1.6 %	
Changes in provisions	0	0	0	0	0	0	0	0	0	0	0	0	0	
Change in Liquidity from														
- Working Capital	1	14	5	5	-7	-3	1	0	5	5	6	4	2	
- Capex	12	12	13	15	16	17	19	20	20	22	22	22	22	
Capex in % of Sales	1.7 %	1.6 %	1.5 %	1.7 %	1.7 %	1.7 %	1.7 %	1.7 %	1.7 %	1.7 %	1.7 %	1.6 %	1.6 %	
- Other	44	10	62	0	0	0	0	0	0	0	0	0	0	
Free Cash Flow (WACC Model)	-10	18	-23	39	52	49	45	47	43	42	45	49	52	53
PV of FCF	-10	15	-18	29	34	29	25	23	19	17	17	17	16	206
share of PVs		-2.99 %						53.89	9 %					49.09 %

Model parameter				Valuation (m)			
Derivation of WACC:		Derivation of Beta:		Present values 2037e	213		
				Terminal Value	206		
Debt ratio	25.00 %	Financial Strength	1.50	Financial liabilities	114		
Cost of debt (after tax)	6.3 %	Liquidity (share)	1.80	Pension liabilities	0		
Market return	8.25 %	Cyclicality	1.30	Hybrid capital	0		
Risk free rate	2.75 %	Transparency	1.60	Minority interest	0		
		Others	1.40	Market val. of investments	0		
				Liquidity	22	No. of shares (m)	20.4
WACC	9.91 %	Beta	1.52	Equity Value	327	Value per share (EUR)	16.02

36113	itivity va	ilue per Sil	are (EUK)													
		Terminal (Growth								Delta EBIT	-margin					
Beta	WACC	1.25 %	1.50 %	1.75 %	2.00 %	2.25 %	2.50 %	2.75 %	Beta \	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.76	10.9 %	12.63	12.83	13.04	13.26	13.49	13.73	13.99	1.76	10.9 %	7.18	9.21	11.23	13.26	15.28	17.30	19.33
1.64	10.4 %	13.82	14.05	14.30	14.55	14.83	15.12	15.43	1.64	10.4 %	8.11	10.26	12.41	14.55	16.70	18.85	21.00
1.58	10.2 %	14.47	14.72	14.98	15.27	15.57	15.89	16.23	1.58	10.2 %	8.61	10.83	13.05	15.27	17.48	19.70	21.92
1.52	9.9 %	15.15	15.42	15.71	16.02	16.35	16.70	17.08	1.52	9.9 %	9.15	11.44	13.73	16.02	18.31	20.60	22.89
1.46	9.7 %	15.88	16.17	16.49	16.83	17.19	17.58	17.99	1.46	9.7 %	9.73	12.10	14.46	16.83	19.20	21.57	23.93
1.40	9.4 %	16.65	16.97	17.32	17.69	18.09	18.52	18.98	1.40	9.4 %	10.34	12.79	15.24	17.69	20.14	22.59	25.04
1.28	8.9 %	18.35	18.74	19.16	19.61	20.10	20.62	21.19	1.28	8.9 %	11.71	14.34	16.98	19.61	22.25	24.88	27.52

- Estimated cash outflows for acquisitions are incorporated in the 2025 "Others" line
- Cash flows in the current year were also adjusted in the "Others" line for positive bargain effects already realized
- Cash outflows from TPG's options to buy its minorities is in the 2026 "Others" line
- Since we assume TPG will aquire 100% of most subsidiaries, we have set the value of the minority interest to zero
- IFRS 16 amortisation is adjusted in "Others"; associated lease liabilities are corrected in the net debt




Valuation							
	2021	2022	2023	2024	2025e	2026e	2027e
Price / Book	2.2 x	1.4 x	1.2 x	1.1 x	1.4 x	1.1 x	1.0 x
Book value per share ex intangibles	2.89	-0.11	-1.58	-0.24	-0.15	1.21	2.76
EV / Sales	0.9 x	0.6 x	0.4 x	0.5 x	0.4 x	0.4 x	0.3 x
EV / EBITDA	28.2 x	6.2 x	3.4 x	4.5 x	5.6 x	4.5 x	3.7 x
EV / EBIT	92.3 x	8.9 x	4.1 x	5.5 x	7.3 x	5.7 x	4.6 x
EV / EBIT adj.*	92.3 x	8.9 x	4.1 x	5.5 x	7.3 x	5.7 x	4.6 x
P/FCF	n.a.	18.4 x	1.8 x	3.0 x	9.2 x	10.5 x	6.5 x
P/E	93.7 x	6.7 x	3.6 x	4.8 x	8.9 x	6.9 x	6.2 x
P / E adj.*	93.7 x	6.7 x	3.6 x	4.8 x	8.9 x	6.9 x	6.2 x
Dividend Yield	n.a.						
FCF Potential Yield (on market EV)	3.5 %	14.9 %	25.4 %	20.8 %	15.6 %	18.8 %	22.5 %



In EUR m	2021	2022	2023	2024	2025e	2026e	2027€
Sales	241	387	441	525	703	784	842
Change Sales yoy	153.9 %	61.0 %	13.8 %	19.0 %	34.1 %	11.4 %	7.5 %
Increase / decrease in inventory	0	0	0	0	0	0	0
Own work capitalised	2	0	0	0	0	0	0
Total Sales	243	387	441	525	703	784	842
Material expenses	160	272	326	356	504	563	604
Gross profit	83	115	115	169	199	221	238
Gross profit margin	34.3 %	29.8 %	26.1 %	32.2 %	28.3 %	28.2 %	28.3 %
Personnel expenses	16	27	22	28	39	43	45
Other operating income	18	29	33	29	13	14	14
Other operating expenses	77	80	78	114	117	127	136
Unfrequent items	0	0	0	0	0	0	0
EBITDA	7	37	47	56	56	65	72
Margin	3.1 %	9.5 %	10.8 %	10.6 %	8.0 %	8.3 %	8.5 %
Depreciation of fixed assets	2	5	4	4	6	6	6
EBITA	5	32	44	51	50	59	66
Amortisation of intangible assets	3	7	4	5	7	8	9
Goodwill amortisation	0	0	0	0	0	0	0
EBIT	2	26	39	46	43	51	57
Margin	0.9 %	6.6 %	8.9 %	8.7 %	6.1 %	6.5 %	6.8 %
EBIT adj.	2	26	39	46	43	51	57
Interest income	0	0	0	0	0	0	0
Interest expenses	1	2	6	9	11	10	10
Other financial income (loss)	0	0	0	0	0	0	0
EBT	2	25	33	36	33	41	47
Margin	0.8 %	6.3 %	7.5 %	6.9 %	4.6 %	5.3 %	5.6 %
Total taxes	0	0	0	1	7	10	12
Net income from continuing operations	2	25	33	36	25	32	35
Income from discontinued operations (net of tax)	0	-3	-6	-3	0	0	0
Net income before minorities	2	21	27	33	25	32	35
Minority interest	0	2	1	2	2	2	2
Net income	2	19	26	31	23	30	33
Margin	0.8 %	5.0 %	5.9 %	5.9 %	3.3 %	3.8 %	3.9 %
Number of shares, average	6	17	17	19	20	20	20
EPS	0.30	1.12	1.50	1.60	1.13	1.45	1.62
EPS adj.	0.30	1.12	1.50	1.60	1.13	1.45	1.62

Guidance: 2025: GMV EUR 1.3bn, sales EUR 680-700m, adj. EBITDA EUR 47-50m


Financial Ratios							
	2021	2022	2023	2024	2025e	2026e	2027e
Total Operating Costs / Sales	97.7 %	90.5 %	89.2 %	89.4 %	92.0 %	91.7 %	91.5 %
Operating Leverage	-0.2 x	17.0 x	3.9 x	0.8 x	-0.2 x	1.7 x	1.6 x
EBITDA / Interest expenses	14.2 x	24.0 x	7.3 x	5.9 x	5.3 x	6.4 x	7.1 x
Tax rate (EBT)	5.3 %	-1.1 %	-1.0 %	2.2 %	22.0 %	24.0 %	26.0 %
Dividend Payout Ratio	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Sales per Employee	403,194	515,900	640,650	762,562	748,697	748,697	762,562





Consolidated balance sheet							
In EUR m	2021	2022	2023	2024	2025e	2026e	2027e
Assets							
Goodwill and other intangible assets	62	91	108	137	154	156	158
thereof other intangible assets	18	59	64	89	107	109	110
thereof Goodwill	44	32	44	47	47	47	47
Property, plant and equipment	10	8	10	18	30	27	24
Financial assets	0	0	0	5	5	5	5
Other long-term assets	0	0	0	0	0	0	0
Fixed assets	72	99	118	159	189	187	186
Inventories	55	127	92	73	83	98	105
Accounts receivable	25	38	55	51	64	69	72
Liquid assets	8	12	8	22	4	23	54
Other short-term assets	12	13	12	17	17	17	17
Current assets	99	191	167	164	167	207	249
Total Assets	171	290	284	323	356	395	435
Liabilities and shareholders' equity							
Subscribed capital	6	18	18	20	20	20	20
Capital reserve	139	51	41	49	49	49	49
Retained earnings	0	9	12	52	75	104	137
Other equity components	-65	11	10	11	7	7	7
Shareholders' equity	80	89	81	132	151	181	214
Minority interest	1	1	1	3	6	8	10
Total equity	81	91	82	135	157	188	223
Provisions	1	5	3	0	0	0	0
thereof provisions for pensions and similar obligations	0	0	0	0	0	0	0
Financial liabilities (total)	41	111	76	123	113	113	113
Short-term financial liabilities	8	36	37	29	29	29	29
Accounts payable	34	31	41	36	58	64	69
Other liabilities	13	52	82	29	29	29	29
Liabilities	90	199	203	188	200	206	211
Total liabilities and shareholders' equity	171	290	284	323	356	395	435


Financial Ratios							
	2021	2022	2023	2024	2025e	2026e	2027e
Efficiency of Capital Employment							
Operating Assets Turnover	4.4 x	2.7 x	3.8 x	4.9 x	5.9 x	6.1 x	6.4 x
Capital Employed Turnover	2.1 x	2.0 x	2.9 x	2.2 x	2.6 x	2.8 x	3.0 x
ROA	2.6 %	19.6 %	22.0 %	19.6 %	12.2 %	15.8 %	17.8 %
Return on Capital							
ROCE (NOPAT)	2.9 %	17.0 %	23.4 %	23.2 %	13.4 %	14.3 %	15.1 %
ROE	2.5 %	22.9 %	30.5 %	29.3 %	16.4 %	17.8 %	16.8 %
Adj. ROE	2.5 %	22.9 %	30.5 %	29.3 %	16.4 %	17.8 %	16.8 %
Balance sheet quality							
Net Debt	34	99	69	101	109	90	58
Net Financial Debt	34	99	69	101	109	90	58
Net Gearing	41.2 %	109.5 %	83.9 %	74.5 %	69.6 %	47.6 %	26.1 %
Net Fin. Debt / EBITDA	454.9 %	268.0 %	144.4 %	180.8 %	194.5 %	137.2 %	81.3 %
Book Value / Share	12.9	5.2	4.7	6.5	7.4	8.9	10.5
Book value per share ex intangibles	2.9	-0.1	-1.6	-0.2	-0.1	1.2	2.8





Consolidated cash flow statement							
In EUR m	2021	2022	2023	2024	2025e	2026e	2027e
Net income	2	21	27	33	25	32	35
Depreciation of fixed assets	2	5	4	4	6	6	6
Amortisation of goodwill	0	0	0	0	0	0	0
Amortisation of intangible assets	3	7	4	5	7	8	9
Increase/decrease in long-term provisions	0	0	0	0	0	0	0
Other non-cash income and expenses	0	0	-19	-7	-4	0	0
Cash Flow before NWC change	7	33	16	36	35	46	49
Increase / decrease in inventory	-33	-72	37	19	-9	-15	-7
Increase / decrease in accounts receivable	-17	-13	-17	8	-13	-5	-3
Increase / decrease in accounts payable	26	-3	36	-5	21	7	5
Increase / decrease in other working capital positions	4	70	0	0	0	0	0
Increase / decrease in working capital (total)	-19	-19	55	22	-1	-14	-5
Net cash provided by operating activities [1]	-13	13	71	58	34	32	44
Investments in intangible assets	-1	0	-14	-4	-10	-10	-10
Investments in property, plant and equipment	-4	-6	-5	-4	-2	-3	-3
Payments for acquisitions	-22	-19	-59	-48	-31	0	0
Financial investments	0	6	0	0	0	0	0
Income from asset disposals	0	0	0	0	0	0	0
Net cash provided by investing activities [2]	-27	-31	-77	-57	-43	-12	-13
Change in financial liabilities	15	-3	1	14	-10	0	0
Dividends paid	0	0	0	0	0	0	0
Purchase of own shares	0	0	0	0	0	0	0
Capital measures	0	28	0	0	0	0	0
Other	-1	-2	0	0	0	0	0
Net cash provided by financing activities [3]	14	22	2	13	-10	0	0
Change in liquid funds [1]+[2]+[3]	-26	5	-4	15	-19	20	31
Effects of exchange-rate changes on cash	0	0	0	0	0	0	0
Cash and cash equivalent at end of period	8	12	8	22	4	23	54

Financial Ratios							
	2021	2022	2023	2024	2025e	2026e	2027e
Cash Flow							
FCF	-18	7	53	50	22	20	31
Free Cash Flow / Sales	- 7.5 %	1.8 %	12.0 %	9.5 %	3.2 %	2.5 %	3.7 %
Free Cash Flow Potential	7	34	41	52	49	55	59
Free Cash Flow / Net Profit	-975.4 %	36.1 %	204.3 %	160.1 %	96.7 %	66.1 %	94.9 %
Interest Received / Avg. Cash	1.1 %	4.3 %	0.1 %	0.1 %	2.3 %	2.3 %	0.8 %
Interest Paid / Avg. Debt	2.5 %	2.0 %	6.9 %	9.5 %	9.0 %	9.0 %	9.0 %
Management of Funds							
Investment ratio	2.3 %	1.7 %	4.2 %	1.5 %	1.7 %	1.6 %	1.5 %
Maint. Capex / Sales	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Capex / Dep	106.0 %	56.9 %	230.6 %	82.4 %	90.9 %	87.9 %	88.8 %
Avg. Working Capital / Sales	13.9 %	23.2 %	27.2 %	18.5 %	12.6 %	12.2 %	12.5 %
Trade Debtors / Trade Creditors	72.2 %	122.7 %	133.2 %	140.6 %	110.0 %	106.7 %	103.3 %
Inventory Turnover	2.9 x	2.1 x	3.5 x	4.9 x	6.1 x	5.7 x	5.7 x
Receivables collection period (days)	37	36	45	36	33	32	31
Payables payment period (days)	78	42	46	37	42	42	42
Cash conversion cycle (Days)	84	165	103	73	51	54	53



Source: Warburg Research Source: Warburg Research Source: Warburg Research



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also http://www.mmwarburg.de/disclaimer/disclaimer/htm#Valuation). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.



Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
- 3. CIC (Crédit Industriel et Commercial) and M.M.Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
- 4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
- 5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or**investment services and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
The Platform Group	5	https://www.mmwarburg.com/disclaimer/disclaimer_en/DE000A2QEFA1.htm



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

<u>"_"</u>	Rating suspended:	The available information currently does not permit an evaluation of the company.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.


Rating	Number of stocks	% of Universe
Buy	141	70
Hold	49	24
Sell	6	3
Rating suspended	5	2
Total	201	100

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	36	72
Hold	10	20
Sell	1	2
Rating suspended	3	6
Total	50	100

PRICE AND RATING HISTORY THE PLATFORM GROUP AS OF 16.06.2025



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



EQUITIES			
Matthias Rode Head of Equities	+49 40 3282-2678 mrode@mmwarburg.com		
RESEARCH			
Michael Heider Head of Research	+49 40 309537-280 mheider@warburg-research.com	Hannes Müller Software, IT	+49 40 309537-255 hmueller@warburg-research.com
Henner Rüschmeier Head of Research Stefan Augustin Cap. Goods, Engineering	+49 40 309537-270 hrueschmeier@warburg-research.com +49 40 309537-168	Andreas Pläsier Banks, Financial Services Malte Schaumann	+49 40 309537-246 aplaesier@warburg-research.com +49 40 309537-170
Jan Bauer Renewables	saugustin@warburg-research.com +49 40 309537-155 jbauer@warburg-research.com	Technology Oliver Schwarz Chemicals, Agriculture	mschaumann@warburg-research.com +49 40 309537-250 oschwarz@warburg-research.com
Christian Cohrs Industrials & Transportation Dr. Christian Ehmann	+49 40 309537-175 ccohrs@warburg-research.com +49 40 309537-167	Simon Stippig Real Estate, Telco Marc-René Tonn	+49 40 309537-265 sstippig@warburg-research.com +49 40 309537-259
Dr. Christian Enmann BioTech, Life Science Felix Ellmann	+49 40 30937-167 cehmann@warburg-research.com +49 40 309537-120	Automobiles, Car Suppliers Robert-Jan van der Horst	+49 40 309537-259 mtonn@warburg-research.com +49 40 309537-290
Software, IT Jörg Philipp Frey Retail, Consumer Goods	fellmann@warburg-research.com +49 40 309537-258	Technology Andreas Wolf Software. IT	rvanderhorst@warburg-research.com +49 40 309537-140
Marius Fuhrberg Financial Services	jfrey@warburg-research.com +49 40 309537-185 mfuhrberg@warburg-research.com	Sulwate, 11	awolf@warburg-research.com
Fabio Hölscher Automobiles, Car Suppliers Philipp Kaiser	+49 40 309537-240 fhoelscher@warburg-research.com +49 40 309537-260		
Real Estate, Construction Thilo Kleibauer	pkaiser@warburg-research.com +49 40 309537-257		
Retail, Consumer Goods INSTITUTIONAL EQUITY	tkleibauer@warburg-research.com		
Klaus Schilling	+49 69 5050-7400	Sascha Propp	+49 40 3282-2656
Head of Equity Sales, Germany Tim Beckmann	kschilling@mmwarburg.com +49 40 3282-2665	France	spropp@mmwarburg.com
United Kingdom Jens Buchmüller Scandinavia, Austria	tbeckmann@mmwarburg.com +49 69 5050-7415 jbuchmueller@mmwarburg.com		
Matthias Fritsch United Kingdom, Ireland	+49 40 3282-2696 mfritsch@mmwarburg.com	Leyan Ilkbahar Roadshow/Marketing	+49 40 3282-2695 lilkbahar@mmwarburg.com
Rudolf Alexander Michaelis Germany	+49 40 3282-2649 rmichaelis@mmwarburg.com	Antonia Möller Roadshow/Marketing	+49 69 5050-7417 amoeller@mmwarburg.com
Roman Alexander Niklas Switzerland, Poland, Italy	+49 69 5050-7412 rniklas@mmwarburg.com	Juliane Niemann Roadshow/Marketing	+49 40 3282-2694 jniemann@mmwarburg.com
SALES TRADING		DESIGNATED SPONSOF	RING
Oliver Merckel Head of Sales Trading Bastian Quast	+49 40 3282-2634 omerckel@mmwarburg.com +49 40 3282-2701	Sebastian Schulz Designated Sponsoring Jörg Treptow	+49 40 3282-2631 sschulz@mmwarburg.com +49 40 3282-2658
Sales Trading Christian Salomon Sales Trading	bquast@mmwarburg.com +49 40 3282-2685 csalomon@mmwarburg.com	Designated Sponsoring	jtreptow@mmwarburg.com
MACRO RESEARCH			
Carsten Klude Macro Research	+49 40 3282-2572 cklude@mmwarburg.com	Dr. Christian Jasperneite Investment Strategy	+49 40 3282-2439 cjasperneite@mmwarburg.com
Our research can be four	nd under:		
<u> </u>	search.mmwarburg.com/en/index.html	LSEG	www.lseg.com
Bloomberg FactSet	RESP MMWA GO www.factset.com	Capital IQ	www.capitaliq.com
For access please contact:			
Andrea Schaper Sales Assistance	+49 40 3282-2632 aschaper@mmwarburg.com	Kerstin Muthig Sales Assistance	+49 40 3282-2703 kmuthig@mmwarburg.com